郭琦;廖国阳;
GUO Qi;LIAO Guo-yang;Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical University;

• 1:中国医学科学院北京协和医学院医学生物学研究所

摘要(Abstract)：

2013年初,中国部分城市和地区出现了禽流感病毒H7N9感染人的病例,截止目前已有超过500人感染H7N9,感染者死亡率约为30%。WHO专家预测,禽流感病毒H7N9可能引起大流行。因此,人用H7N9禽流感疫苗的研发刻不容缓。目前已有多个H7N9疫苗备选株通过了WHO安全性评价,可用于疫苗研发。在此基础上,H7N9灭活疫苗、减毒活疫苗以及重组疫苗均已取得较好的研究结果。本文对人用H7N9禽流感疫苗的研究进展作一综述。
In early 2013, a novel avian influenza virus(H7N9)strain was discovered in some parts of East China, which caused more than 500 cases of infection and a mortality of about 30% in humans. The experts of WHO predicted that the novel avian influenza virus(H7N9) strain may cause a pandemic, therefore the development of H7N9 vaccine is eagerly needed. At present, couples of candidate H7N9 vaccine strains have passed the safety evaluation by the WHO and may be used for the vaccine development. On the basis of this, satisfactory results have been obtained in the development of inactivated, live attenuated and recombinant avian influenza H7N9 vaccines. This paper reviews the progress in research on avian influenza H7N9 vaccine.

关键词(KeyWords)： 流感病毒;H7N9;疫苗
Influenza virus;H7N9;Vaccine

Abstract:

Keywords:

基金项目(Foundation): 国家高技术研究发展项目(“863”计划)项目(2012AA02A404);; 国家科技部国际科技合作项目(2011DFR30420)

作者(Authors): 郭琦;廖国阳;
GUO Qi;LIAO Guo-yang;Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical University;

DOI: 10.13200/j.cnki.cjb.001669

参考文献(References)：

• [1]WHO.Human infection with avian influenza A(H7N9)virusChin[OL].(2016-02-10)[2016-02-14].http://www.who.int/csr/don/10-february-2016-avian-influenza-china/en/.
• [2]CHEN Y,LIANG W,YANG S,et al.Human infections with the emerging avian influenza A H7N9 virus from wet market poultry:clinical analysis and characterisation of viral genome[J].Lancet,2013,381(9881):1916-1925.
• [3]XU R,DE VRIES R P,ZHU X,et al.Preferential recognition of avian-like receptors in human influenza A H7N9 viruses[J].Science,2013,342(6163):1230-1235.
• [4]ZHU J,WANG D,GAO R,et al.Biological features of novel avian influenza A(H7N9)virus[J].Nature,2013,499(7459):500-503.
• [5]LIU J,XIAO H,WU Y,et al.H7N9:a low pathogenic avian influenza A virus infecting humans[J].Curr Opin Virol,2014,5(4):91-97.
• [6]LIN P H,CHAO T L,KUO S W,et al.Virological,serological,and antiviral studies in an imported human case of avian influenza A(H7N9)virus in Taiwan[J].Clin Infect Dis,2014,58(2):242-246.
• [7]HU Y,LU S,SONG Z,et al.Association between adverse clinical outcome in human disease caused by novel influenza AH7N9 virus and sustained viral shedding and emergence of antiviral resistance[J].Lancet,2013,381(9885):2273-2279.
• [8]杨娟,郑亚明,冯录召,等.人用H7N9禽流感疫苗研发进展[J].中华预防医学杂志,2014,48(2):157-160.
• [9]RIDENOUR C,JOHNSON A,WINNE E,et al.Development of influenza A(H7N9)candidate vaccine viruses with improved hemagglutinin antigen yield in eggs[J].Influenza Other Respir Viruses,2015,9(5):263-270.
• [10]WHO.Summary of status of development and availability ofavian influenza A(H7N9)candidate vaccine viruses[OL].(2015-03-17)[2016-02-14].http://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_a_h7n9_cvv_20150317.pdfua=1.
• [11]NAKAMURA K,SHIRAKURA M,SUZUKI Y,et al.Development of a high-yield reassortant influenza vaccine virus derived from the A/Anhui/1/2013(H7N9)strain[J].Vaccine,2016,34(3):328-333.
• [12]CHIA M Y,HU A Y,TSENG Y F,et al.Evaluation of MDCKcell-derived influenza H7N9 vaccine candidates in ferrets[J].PLo S One,2015,10(3):e0120793.doi:10.1371/journal.pone.0120793.
• [13]WODAL W,SCHWENDINGER M G,SAVIDIS-DACHO H,et al.Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs[J].PLo S One,2015,10(2):e0113963.doi:10.1371/journal.pone.0113963.
• [14]WONG S S,JEEVAN T,KERCHER L,et al.A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets[J].Vaccine,2014,32(35):4571-4577.
• [15]DUAN Y,GU H,CHEN R,et al.Response of mice and ferrets to a monovalent influenza A(H7N9)split vaccine[J].PLo S One,2014,9(6):e99322.doi:10.1371/journal.pone.0099322.
• [16]AMBROSE C S,LEVIN M J,BELSHE R B.The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults[J].Influenza Other Respir Viruses,2011,5(2):67-75.
• [17]BELSHE R B,EDWARDS K M,VESIKARI T,et al.Live attenuated versus inactivated influenza vaccine in infants and young children[J].N Engl J Med,2007,356(7):685-696.
• [18]DE JONGE J,ISAKOVA-SIVAK I,VAN DIJKEN H,et al.H7N9 live attenuated influenza vaccine is highly immunogenic,prevents virus replication and protects against severe bronchopneumonia in ferrets[J].Mol Ther,2016,24(5):991-1002.
• [19]YANG X,ZHAO J,WANG C,et al.Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge[J].PLo S One,2015,10(4):e0123659.doi:10.1371/journal.pone.0123659.
• [20]KONG H,ZHANG Q,GU C,et al.A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals[J].Sci Rep,2015,5(6):11233.
• [21]TREANOR J J,EI SAHLY H,KING J,et al.Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine(Flu Blok~)against influenza in healthy adults:a randomized,placebo-controlled trial[J].Vaccine,2011,29(44):7733-7739.
• [22]BLANCHFIELD K,KAMAL R P,TZENG W P,et al.Recombinant influenza H7 hemagglutinins induce lower neutralizing antibody titers in mice than do seasonal hemagglutinins[J].Influenza Other Respir Viruses,2014,8(6):628-635.
• [23]CAO W,LIEPKALNS J S,HASSAN A O,et al.A highly immunogenic vaccine against A/H7N9 influenza virus[J].Vaccine,2016,34(6):744-749.
• [24]YANG P,WANG W,GU H,et al.Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60protein vaccine construct in BALB/c mice[J].Antiviral Res,2014,111(11):1-7.
• [25]LIU Y V,MASSARE M J,PEARCE M B,et al.Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9)virus infection in ferrets[J].Vaccine,2015,33(18):2152-2158.
• [26]SMITH G E,FLYER D C,RAGHUNANDAN R,et al.Development of influenza H7N9 virus like particle(VLP)vaccine:homologous A/Anhui/1/2013(H7N9)protection and heterologous A/chicken/Jalisco/CPA1/2012(H7N3)crossprotection in vaccinated mice challenged with H7N9 virus[J].Vaccine,2013,31(40):4305-4313.
• [27]RUDENKO L,ISAKOVA-SIVAK I,NAYKHIN A,et al.H7N9 live attenuated influenza vaccine in healthy adults:a randomised,double-blind,placebo-controlled,phase 1 trial[J].Lancet Infect Dis,2016,16(3):303-310.
• [28]Novartis Vaccines.Dose-finding study of four dosage levels of an H7N9 influenza vaccine in adults between ages of 18 years and 65 years[OL].(2015-03-05)[2016-02-14].http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01928472.
• [29]BART S A,HOHENBOKEN M,DELLA CIOPPA G,et al.Acell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults[J].Sci Transl Med,2014,6(234):234ra55.doi:10.1126/scitranslmed.3008761.
• [30]JACKSON L A,CAMPBELL J D,FREY S E,et al.Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response:a randomized clinical trial[J].JAMA,2015,314(3):237-246.
• [31]COX R J,PEDERSEN G,MADHUN A S,et al.Evaluation of a virosomal H5N1 vaccine formulated with Matrix M?adjuvant in a phase I clinical trial[J].Vaccine,2011,29(45):8049-8059.
• [32]HUSAIN M.Avian influenza A(H7N9)virus infection in humans:epidemiology,evolution,and pathogenesis[J].Infect Genet Evol,2014,28(12):304-312.
• [33]BARRETT P N,PORTSMOUTH D,EHRLICH H J.Vero cell culture-derived pandemic influenza vaccines:preclinical and clinical development[J].Expert Rev Vaccines,2013,12(4):395-413.